The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.
Identifieur interne : 007E62 ( Main/Exploration ); précédent : 007E61; suivant : 007E63The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.
Auteurs : Madsen Beau De Rochars [Haïti] ; Sanjat Kanjilal ; Abdel N. Direny ; Jeanne Radday ; Jack G. Lafontant ; Els Mathieu ; Richard D. Rheingans ; Anne C. Haddix ; Thomas G. Streit ; Michael J. Beach ; David G. Addiss ; Patrick J. LammieSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 2005.
Descripteurs français
- KwdFr :
- Albendazole (administration et posologie), Albendazole (usage thérapeutique), Albendazole (économie), Animaux, Association de médicaments, Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (usage thérapeutique), Diéthylcarbamazine (économie), Filaricides (administration et posologie), Filaricides (usage thérapeutique), Filaricides (économie), Filariose lymphatique (), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (économie), Filariose lymphatique (épidémiologie), Haïti, Humains, Microfilaria (), Microfilaria (croissance et développement), Programmes gouvernementaux (économie), Surveillance sentinelle, Wuchereria bancrofti (), Éducation pour la santé, Évaluation de programme.
- MESH :
- administration et posologie : Albendazole, Diéthylcarbamazine, Filaricides.
- croissance et développement : Microfilaria.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Diéthylcarbamazine, Filaricides.
- économie : Albendazole, Diéthylcarbamazine, Filaricides, Filariose lymphatique, Programmes gouvernementaux.
- épidémiologie : Filariose lymphatique.
- Animaux, Association de médicaments, Filariose lymphatique, Haïti, Humains, Microfilaria, Surveillance sentinelle, Wuchereria bancrofti, Éducation pour la santé, Évaluation de programme.
English descriptors
- KwdEn :
- Albendazole (administration & dosage), Albendazole (economics), Albendazole (therapeutic use), Animals, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (economics), Diethylcarbamazine (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (economics), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (prevention & control), Filaricides (administration & dosage), Filaricides (economics), Filaricides (therapeutic use), Government Programs (economics), Haiti, Health Education, Humans, Microfilariae (drug effects), Microfilariae (growth & development), Program Evaluation, Sentinel Surveillance, Wuchereria bancrofti (drug effects).
- MESH :
- chemical , administration & dosage : Albendazole, Diethylcarbamazine, Filaricides.
- chemical , economics : Albendazole, Diethylcarbamazine, Filaricides.
- chemical , therapeutic use : Albendazole, Diethylcarbamazine, Filaricides.
- drug effects : Microfilariae, Wuchereria bancrofti.
- drug therapy : Elephantiasis, Filarial.
- economics : Elephantiasis, Filarial, Government Programs.
- epidemiology : Elephantiasis, Filarial.
- growth & development : Microfilariae.
- prevention & control : Elephantiasis, Filarial.
- Animals, Drug Therapy, Combination, Haiti, Health Education, Humans, Program Evaluation, Sentinel Surveillance.
Abstract
To support the global program to eliminate lymphatic filariasis (LF), well-monitored demonstration projects are important for defining the relationship between coverage and reductions in microfilaremia. We are using mass treatment with diethylcarbamazine (DEC) and albendazole in an effort to eliminate LF from Leogane, Haiti. Wuchereria bancrofti microfilaremia prevalence at baseline ranged from 0.8% to 15.9% in four sentinel sites. After three rounds of DEC-albendazole mass drug administration (MDA), both microfilaremia prevalence and intensity decreased dramatically. Mild and moderate adverse reactions after treatment were common, especially after the first MDA, but decreased after subsequent MDAs. Drug coverage for the first year was estimated to be 72%, but concerns about adverse reactions appeared to decrease drug coverage in the second MDA. As a result of community education efforts that focused on providing a greater understanding of adverse reactions, coverage increased dramatically for the third round. Program efficiency increased substantially; the costs per person treated for three rounds of MDA were 2.23 US dollars, 1.96 US dollars, and 1.30 US dollars per person, respectively. The Leogane experience highlights the importance of adapting community education and mobilization campaigns to achieve and maintain good coverage.
PubMed: 16282299
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003B56
- to stream PubMed, to step Curation: 003B56
- to stream PubMed, to step Checkpoint: 003B56
- to stream Ncbi, to step Merge: 002023
- to stream Ncbi, to step Curation: 002023
- to stream Ncbi, to step Checkpoint: 002023
- to stream Main, to step Merge: 008066
- to stream Main, to step Curation: 007E62
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.</title><author><name sortKey="De Rochars, Madsen Beau" sort="De Rochars, Madsen Beau" uniqKey="De Rochars M" first="Madsen Beau" last="De Rochars">Madsen Beau De Rochars</name><affiliation wicri:level="1"><nlm:affiliation>Hopital Ste. Croix, Leogane, Haiti.</nlm:affiliation><country xml:lang="fr">Haïti</country><wicri:regionArea>Hopital Ste. Croix, Leogane</wicri:regionArea><wicri:noRegion>Leogane</wicri:noRegion></affiliation></author><author><name sortKey="Kanjilal, Sanjat" sort="Kanjilal, Sanjat" uniqKey="Kanjilal S" first="Sanjat" last="Kanjilal">Sanjat Kanjilal</name></author><author><name sortKey="Direny, Abdel N" sort="Direny, Abdel N" uniqKey="Direny A" first="Abdel N" last="Direny">Abdel N. Direny</name></author><author><name sortKey="Radday, Jeanne" sort="Radday, Jeanne" uniqKey="Radday J" first="Jeanne" last="Radday">Jeanne Radday</name></author><author><name sortKey="Lafontant, Jack G" sort="Lafontant, Jack G" uniqKey="Lafontant J" first="Jack G" last="Lafontant">Jack G. Lafontant</name></author><author><name sortKey="Mathieu, Els" sort="Mathieu, Els" uniqKey="Mathieu E" first="Els" last="Mathieu">Els Mathieu</name></author><author><name sortKey="Rheingans, Richard D" sort="Rheingans, Richard D" uniqKey="Rheingans R" first="Richard D" last="Rheingans">Richard D. Rheingans</name></author><author><name sortKey="Haddix, Anne C" sort="Haddix, Anne C" uniqKey="Haddix A" first="Anne C" last="Haddix">Anne C. Haddix</name></author><author><name sortKey="Streit, Thomas G" sort="Streit, Thomas G" uniqKey="Streit T" first="Thomas G" last="Streit">Thomas G. Streit</name></author><author><name sortKey="Beach, Michael J" sort="Beach, Michael J" uniqKey="Beach M" first="Michael J" last="Beach">Michael J. Beach</name></author><author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name></author><author><name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J" last="Lammie">Patrick J. Lammie</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16282299</idno><idno type="pmid">16282299</idno><idno type="wicri:Area/PubMed/Corpus">003B56</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B56</idno><idno type="wicri:Area/PubMed/Curation">003B56</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003B56</idno><idno type="wicri:Area/PubMed/Checkpoint">003B56</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003B56</idno><idno type="wicri:Area/Ncbi/Merge">002023</idno><idno type="wicri:Area/Ncbi/Curation">002023</idno><idno type="wicri:Area/Ncbi/Checkpoint">002023</idno><idno type="wicri:doubleKey">0002-9637:2005:De Rochars M:the:leogane:haiti</idno><idno type="wicri:Area/Main/Merge">008066</idno><idno type="wicri:Area/Main/Curation">007E62</idno><idno type="wicri:Area/Main/Exploration">007E62</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.</title><author><name sortKey="De Rochars, Madsen Beau" sort="De Rochars, Madsen Beau" uniqKey="De Rochars M" first="Madsen Beau" last="De Rochars">Madsen Beau De Rochars</name><affiliation wicri:level="1"><nlm:affiliation>Hopital Ste. Croix, Leogane, Haiti.</nlm:affiliation><country xml:lang="fr">Haïti</country><wicri:regionArea>Hopital Ste. Croix, Leogane</wicri:regionArea><wicri:noRegion>Leogane</wicri:noRegion></affiliation></author><author><name sortKey="Kanjilal, Sanjat" sort="Kanjilal, Sanjat" uniqKey="Kanjilal S" first="Sanjat" last="Kanjilal">Sanjat Kanjilal</name></author><author><name sortKey="Direny, Abdel N" sort="Direny, Abdel N" uniqKey="Direny A" first="Abdel N" last="Direny">Abdel N. Direny</name></author><author><name sortKey="Radday, Jeanne" sort="Radday, Jeanne" uniqKey="Radday J" first="Jeanne" last="Radday">Jeanne Radday</name></author><author><name sortKey="Lafontant, Jack G" sort="Lafontant, Jack G" uniqKey="Lafontant J" first="Jack G" last="Lafontant">Jack G. Lafontant</name></author><author><name sortKey="Mathieu, Els" sort="Mathieu, Els" uniqKey="Mathieu E" first="Els" last="Mathieu">Els Mathieu</name></author><author><name sortKey="Rheingans, Richard D" sort="Rheingans, Richard D" uniqKey="Rheingans R" first="Richard D" last="Rheingans">Richard D. Rheingans</name></author><author><name sortKey="Haddix, Anne C" sort="Haddix, Anne C" uniqKey="Haddix A" first="Anne C" last="Haddix">Anne C. Haddix</name></author><author><name sortKey="Streit, Thomas G" sort="Streit, Thomas G" uniqKey="Streit T" first="Thomas G" last="Streit">Thomas G. Streit</name></author><author><name sortKey="Beach, Michael J" sort="Beach, Michael J" uniqKey="Beach M" first="Michael J" last="Beach">Michael J. Beach</name></author><author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name></author><author><name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J" last="Lammie">Patrick J. Lammie</name></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="ISSN">0002-9637</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (administration & dosage)</term><term>Albendazole (economics)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (economics)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (economics)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Filaricides (administration & dosage)</term><term>Filaricides (economics)</term><term>Filaricides (therapeutic use)</term><term>Government Programs (economics)</term><term>Haiti</term><term>Health Education</term><term>Humans</term><term>Microfilariae (drug effects)</term><term>Microfilariae (growth & development)</term><term>Program Evaluation</term><term>Sentinel Surveillance</term><term>Wuchereria bancrofti (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (administration et posologie)</term><term>Albendazole (usage thérapeutique)</term><term>Albendazole (économie)</term><term>Animaux</term><term>Association de médicaments</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Diéthylcarbamazine (économie)</term><term>Filaricides (administration et posologie)</term><term>Filaricides (usage thérapeutique)</term><term>Filaricides (économie)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (économie)</term><term>Filariose lymphatique (épidémiologie)</term><term>Haïti</term><term>Humains</term><term>Microfilaria ()</term><term>Microfilaria (croissance et développement)</term><term>Programmes gouvernementaux (économie)</term><term>Surveillance sentinelle</term><term>Wuchereria bancrofti ()</term><term>Éducation pour la santé</term><term>Évaluation de programme</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Microfilaria</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Microfilariae</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Government Programs</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Microfilariae</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term><term>Filariose lymphatique</term><term>Programmes gouvernementaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Therapy, Combination</term><term>Haiti</term><term>Health Education</term><term>Humans</term><term>Program Evaluation</term><term>Sentinel Surveillance</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Association de médicaments</term><term>Filariose lymphatique</term><term>Haïti</term><term>Humains</term><term>Microfilaria</term><term>Surveillance sentinelle</term><term>Wuchereria bancrofti</term><term>Éducation pour la santé</term><term>Évaluation de programme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To support the global program to eliminate lymphatic filariasis (LF), well-monitored demonstration projects are important for defining the relationship between coverage and reductions in microfilaremia. We are using mass treatment with diethylcarbamazine (DEC) and albendazole in an effort to eliminate LF from Leogane, Haiti. Wuchereria bancrofti microfilaremia prevalence at baseline ranged from 0.8% to 15.9% in four sentinel sites. After three rounds of DEC-albendazole mass drug administration (MDA), both microfilaremia prevalence and intensity decreased dramatically. Mild and moderate adverse reactions after treatment were common, especially after the first MDA, but decreased after subsequent MDAs. Drug coverage for the first year was estimated to be 72%, but concerns about adverse reactions appeared to decrease drug coverage in the second MDA. As a result of community education efforts that focused on providing a greater understanding of adverse reactions, coverage increased dramatically for the third round. Program efficiency increased substantially; the costs per person treated for three rounds of MDA were 2.23 US dollars, 1.96 US dollars, and 1.30 US dollars per person, respectively. The Leogane experience highlights the importance of adapting community education and mobilization campaigns to achieve and maintain good coverage.</div></front></TEI><affiliations><list><country><li>Haïti</li></country></list><tree><noCountry><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name><name sortKey="Beach, Michael J" sort="Beach, Michael J" uniqKey="Beach M" first="Michael J" last="Beach">Michael J. Beach</name><name sortKey="Direny, Abdel N" sort="Direny, Abdel N" uniqKey="Direny A" first="Abdel N" last="Direny">Abdel N. Direny</name><name sortKey="Haddix, Anne C" sort="Haddix, Anne C" uniqKey="Haddix A" first="Anne C" last="Haddix">Anne C. Haddix</name><name sortKey="Kanjilal, Sanjat" sort="Kanjilal, Sanjat" uniqKey="Kanjilal S" first="Sanjat" last="Kanjilal">Sanjat Kanjilal</name><name sortKey="Lafontant, Jack G" sort="Lafontant, Jack G" uniqKey="Lafontant J" first="Jack G" last="Lafontant">Jack G. Lafontant</name><name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J" last="Lammie">Patrick J. Lammie</name><name sortKey="Mathieu, Els" sort="Mathieu, Els" uniqKey="Mathieu E" first="Els" last="Mathieu">Els Mathieu</name><name sortKey="Radday, Jeanne" sort="Radday, Jeanne" uniqKey="Radday J" first="Jeanne" last="Radday">Jeanne Radday</name><name sortKey="Rheingans, Richard D" sort="Rheingans, Richard D" uniqKey="Rheingans R" first="Richard D" last="Rheingans">Richard D. Rheingans</name><name sortKey="Streit, Thomas G" sort="Streit, Thomas G" uniqKey="Streit T" first="Thomas G" last="Streit">Thomas G. Streit</name></noCountry><country name="Haïti"><noRegion><name sortKey="De Rochars, Madsen Beau" sort="De Rochars, Madsen Beau" uniqKey="De Rochars M" first="Madsen Beau" last="De Rochars">Madsen Beau De Rochars</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007E62 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007E62 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16282299
|texte= The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16282299" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |